MP30-15 PREVALENCE OF URINARY TRACT INFECTIONS IN WOMEN WITH GENITOURINARY SYNDROME OF MENOPAUSE AND THE IMPACT OF VAGINAL PRASTERONE ON URINARY TRACT INFECTIONS (2020)

You have accessJournal of UrologyUrodynamics/Lower Urinary Tract Dysfunction/Female Pelvic Medicine: Female Incontinence: Therapy I (MP30)1 Apr 2020MP30-15 PREVALENCE OF URINARY TRACT INFECTIONS IN WOMEN WITH GENITOURINARY SYNDROME OF MENOPAUSE AND THE IMPACT OF VAGINAL PRASTERONE ON URINARY TRACT INFECTIONS Rachel Rubin*, Erick Moyneur, May Lee Tjoa, Amama Sadiq, Fernand Labrie, and Alain Dury Rachel Rubin*Rachel Rubin* More articles by this author , Erick MoyneurErick Moyneur More articles by this author , May Lee TjoaMay Lee Tjoa More articles by this author , Amama SadiqAmama Sadiq More articles by this author , Fernand LabrieFernand Labrie More articles by this author , and Alain DuryAlain Dury More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000000869.015AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Recurrent urinary tract infections (UTIs) are associated with genitourinary syndrome of menopause (GSM) in postmenopausal women. Androgens, in addition to estrogens, have an impact on female genitourinary tissues and may decrease the recurrence risk of UTIs. Vaginal prasterone, an FDA-approved synthetic form of endogenous DHEA, can be converted into active androgens and estrogens. The objectives of this study were 1) to evaluate the prevalence of UTIs in women newly diagnosed with GSM versus women without GSM, and 2) to assess the prevalence of UTIs in women treated with prasterone versus untreated women. METHODS: This was a retrospective cohort analysis using data from Integrated Dataverse database from Symphony Health Solutions collected between 02/2015 and 06/2019. Data was analyzed from women at least 45 years old and who have at least one year of clinical data before and after their index dates. For objective 1, index dates were defined as the first observed GSM diagnosis for the GSM cohort and as a randomly selected outpatient visit date for women without a GSM diagnosis. For objective 2, index dates were defined as the first prasterone fill date for treated women and as the initial GSM diagnosis date for untreated women. To ensure women had a balanced UTI risk profile, women treated with prasterone were matched to untreated women based on age, region, diabetes history, and number of UTI episodes in the year prior to the index date. The UTI prevalence was measured over a 1-year period after the index date. The differential prevalence was assessed using risk ratios (RR). RESULTS: The prevalence of UTIs was threefold higher (RR 3.0, 95%CI 2.97-3.04) in women diagnosed with GSM compared to matched controls (N=413,207). Women with untreated GSM (N=5,813) had an increased frequency of UTI episodes in the 12 months following the first observed GSM diagnosis (p<0.05) compared to their baseline. When compared to women with untreated GSM, women treated with prasterone had a significantly lower UTI prevalence within 12 months of the first prescription fill (RR 0.62, 95% CI (0.56 – 0.68), p<0.05). CONCLUSIONS: Women newly diagnosed with GSM have a higher rate of UTIs compared to women without GSM. Results also suggest that the use of prasterone in women diagnosed with GSM may reduce the recurrence of UTIs. Source of Funding: AMAG Pharmaceuticals, Inc. provided funding for this study. © 2020 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 203Issue Supplement 4April 2020Page: e443-e444 Advertisement Copyright & Permissions© 2020 by American Urological Association Education and Research, Inc.MetricsAuthor Information Rachel Rubin* More articles by this author Erick Moyneur More articles by this author May Lee Tjoa More articles by this author Amama Sadiq More articles by this author Fernand Labrie More articles by this author Alain Dury More articles by this author Expand All Advertisement PDF downloadLoading ...